Benzinga | Jul 31, 2020 01:03PM EDT

Oppenheimer Initiates Coverage On Flexion Therapeutics with Outperform Rating, Announces Price Target of $19

Oppenheimer analyst Francois Brisebois initiates coverage on Flexion Therapeutics (NASDAQ:FLXN) with a Outperform rating and announces Price Target of $19.